BioSpace News Archive

The lawsuit alleges that Pfizer infringed GSK’s patents on respiratory syncytial virus shots. The complaint comes just months after both companies had their respective RSV vaccines approved.

The biopharma company reported sales of $2.24 billion in the second quarter for the cystic fibrosis treatment, beating analysts’ estimate, after it won FDA approval in children ages two to five in April.

Following reports of destroyed and discarded data, the U.S. regulator issued a warning letter to India’s Intas Pharmaceuticals regarding violations of current good manufacturing practice.

Following a year-long legal battle, Illumina is dropping the intellectual property allegations against Guardant. The companies have also entered into a new long-term purchase and supply commitment.

Early research and anecdotal evidence indicate that the popular diabetes and obesity drugs could treat some patients with addictive disorders.

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report second quarter 2023 financial results on Thursday, August 10, 2023, prior to the open of the market.

Paratek Pharmaceuticals, Inc. announced that it has filed definitive proxy materials and a letter to Paratek stockholders with the U.S. Securities and Exchange Commission in connection with the Company’s previously announced definitive agreement to be acquired by Gurnet Point Capital and Novo Holdings A/S.

MIRA Pharmaceuticals, Inc. announced the pricing of its initial public offering of 1,275,000 shares of common stock at an initial public offering price of $7.00 per share for aggregate gross proceeds of $8.9 million, prior to deducting underwriting discounts, commissions and other offering expenses.

Arbele presented early safety data from its first-in-class CDH17xCD3 bispecific T-cell engager antibody, ARB202, at the ASCO Breakthrough conference in Yokohama, Japan.

SK Biopharmaceuticals, a global biotech company, announced the formation of its Scientific Advisory Board, comprising of five prominent experts in oncology, epilepsy, and radiopharmaceutical therapy.